. 2022 Feb 16;7(2):100398. doi: 10.1016/j.esmoop.2022.100398

Table 1.

Reported results of phase III trials included in the meta-analysis

Trial ID (NCT no.)	Experimental arm therapy	Control arm therapy	Cancer target	Oncogene target	Line of therapy	Experimental Arm				Control Arm				PFS HR	OS HR
Trial ID (NCT no.)	Experimental arm therapy	Control arm therapy	Cancer target	Oncogene target	Line of therapy	N	ORR	mPFS (months)	mOS (months)	N	ORR	mPFS (months)	mOS (months)	PFS HR	OS HR
00949650⁵	Afatinib	Pemetrexed/cisplatin	NSCLC	EGFR	1	230	0.565	11.17	28.16	115	0.226	6.90	28.22	0.576	0.880
01121393¹¹	Afatinib	Gemcitabine/cisplatin	NSCLC	EGFR	1	242	0.678	11.01	23.10	122	0.230	5.59	23.46	0.281	0.904
02604342¹²	Alectinib	Pemetrexed or docetaxel	NSCLC	ALK	3	79	0.506	10.9	27.8	40	0.025	1.4	NE	0.20	NE
01154140¹³	Crizotinib	Pemetrexed/platinum	NSCLC	ALK	1	172	0.744	10.9	NE	171	0.450	7.0	47.5	0.454	0.76
01639001¹⁴	Crizotinib	Pemetrexed/platinum	NSCLC	ALK	1	104	0.875	11.1	28.5	103	0.456	6.8	27.7	0.402	0.897
00932893⁶	Crizotinib	Pemetrexed or docetaxel	NSCLC	ALK	2	173	0.653	7.7	21.7	174	0.195	3.0	21.9	0.487	0.854
01227889¹⁵	Dabrafenib	Dacarbazine	Melanoma	BRAF	1	187	0.599	6.9	20.0	63	0.238	2.7	15.6	0.40	0.82
01000025^a ¹⁰	Dacomitinib	Placebo	NSCLC	EGFR	2-4	114	0.114	3.52	7.23	68	0.015	0.95	7.52	0.48	0.98
01342965¹⁶	Erlotinib	Gemcitabine/cisplatin	NSCLC	EGFR	1	110	0.627	11.0	26.3	107	0.336	5.5	25.5	0.34	0.91
00883779^a ¹⁷	Erlotinib/gemcitabine/platinum	Placebo/gemcitabine/platinum	NSCLC	EGFR	1	49	0.84	16.8	30.3	48	0.15	6.9	20.6	0.25	0.72
00322452^a ⁸	Gefitinib	Carboplatin/paclitaxel	NSCLC	EGFR	1	132	0.712	NR	NR	129	0.473	NR	NR	0.48	0.78
01544179¹⁸	Gefitinib/pemetrexed/cisplatin	Placebo/pemetrexed/cisplatin	NSCLC	EGFR	2	133	0.316	5.4	14.8	132	0.341	5.4	17.2	0.86	1.62
IRIS^b ⁹	Imatinib	Interferon/cytarabine	CML	BCR-ABL	1	553	0.953	NR	NR	553	0.555	NR	NR	0.378	NR
02151981¹⁹	Osimertinib	Pemetrexed/platinum	NSCLC	EGFR T790M	2	279	0.706	10.1	26.8	140	0.314	4.4	22.5	0.30	0.87
02959749²⁰	Osimertinib	Docetaxel/bevacizumab	NSCLC	EGFR T790M	3	74	0.616	10.2	15.65	73	0.083	2.95	15.29	0.23	0.79

Note: Values are provided in this table as reported on ClinicalTrials.gov or in the reference, with no rounding.

CML, chronic myeloid leukemia; HR, hazard ratio; ID, identification; mOS, median overall survival; mPFS, median progression-free survival; NCT, National Clinical Trial; NE, non-estimable; NR, not reported at the time of the analysis; NSCLC, non-small-cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.

Data derived from a trial subgroup.

No NCT number.